Theory and strategy for Pneumococcal vaccines in the elderly

References

• World Health Statistics 2014. Available from: http://www.who.int/gho/publications/world_health_statistics/en/
   Google Scholar
• Beard JR, Bloom DE. Towards a comprehensive public health response to population ageing. Lancet 2015; 385:658-61; PMID:25468151; http://dx.doi.org/10.1016/S0140-6736(14)61461-6
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27-72; PMID:17278083; http://dx.doi.org/10.1086/511159
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416; PMID:15699079; http://dx.doi.org/10.1164/rccm.200405-644ST
   PubMed Web of Science ®Google Scholar
• DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. J Crit Care 2015; 30:40-8; PMID:25129577; http://dx.doi.org/10.1016/j.jcrc.2014.07.011
   PubMed Web of Science ®Google Scholar
• Viasus D, Marinescu C, Villoslada A, Cordero E, Galvez-Acebal J, Farinas MC, Gracia-Ahufinger I, Fernandez-Navarro A, Niubo J, Ortega L, et al. Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study. J Infect 2013; 67:185-93; PMID:23747416; http://dx.doi.org/10.1016/j.jinf.2013.05.006
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 Suppl 4:S296-304; PMID:21460288; http://dx.doi.org/10.1093/cid/cir045
   PubMed Web of Science ®Google Scholar
• McMorrow ML, Wemakoy EO, Tshilobo JK, Emukule GO, Mott JA, Njuguna H, Waiboci L, Heraud JM, Rajatonirina S, Razanajatovo NH, et al. Severe acute respiratory illness deaths in sub-saharan Africa and the role of influenza: a case series from 8 countries. J Infect Dis 2015; PMID:25712970; http://dx.doi.org/10.1093/infdis/jiv100
   PubMed Web of Science ®Google Scholar
• Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19:216-28; PMID:23524477; http://dx.doi.org/10.1097/MCP.0b013e32835f27be
   PubMed Web of Science ®Google Scholar
• Ciruela P, Martinez A, Izquierdo C, Hernandez S, Broner S, Munoz-Almagro C, Dominguez A. Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines. Hum Vaccin Immunother 2013; 9:681-91; PMID:23303166; http://dx.doi.org/10.4161/hv.23266
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730
   PubMed Web of Science ®Google Scholar
• Yother J. Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu Rev Microbiol 2011; 65:563-81; PMID:21721938; http://dx.doi.org/10.1146/annurev.micro.62.081307.162944
   PubMed Web of Science ®Google Scholar
• Chiba N, Kobayashi R, Hasegawa K, Morozumi M, Nakayama E, Tajima T, Iwata S, Ubukata K. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. J Antimicrob Chemother 2005; 56:756-60; PMID:16131518; http://dx.doi.org/10.1093/jac/dki302
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez Mdel M, Vazquez F, Mendez FJ. Streptococcus pneumoniae virulence factors and their clinical impact: an update. Enferm Infecc Microbiol Clin 2006; 24:512-7; PMID:16987470; http://dx.doi.org/10.1157/13092469
   PubMed Web of Science ®Google Scholar
• Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010; 78:704-15; PMID:19948837; http://dx.doi.org/10.1128/IAI.00881-09
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K. Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis 2014; 20:1132-9; PMID:24960150
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 2014; 32:2399-405; PMID:24637174; http://dx.doi.org/10.1016/j.vaccine.2014.02.096
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Ruckinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692-9; PMID:20715907; http://dx.doi.org/10.1086/655828
   PubMed Web of Science ®Google Scholar
• Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3–a retrospective epidemiological study. BMC Infect Dis 2013; 13:492; PMID:24148181; http://dx.doi.org/10.1186/1471-2334-13-492
   PubMed Web of Science ®Google Scholar
• Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis 2013; 17:e364-73; PMID:23416209; http://dx.doi.org/10.1016/j.ijid.2013.01.004
   PubMed Web of Science ®Google Scholar
• Skoczynska A, Kuch A, Sadowy E, Wasko I, Markowska M, Ronkiewicz P, Matynia B, Bojarska A, Wasiak K, Golebiewska A, et al. Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur J Clin Microbiol Infect Dis 2015; 34:779-87; PMID:25475124; http://dx.doi.org/10.1007/s10096-014-2283-8
   PubMed Web of Science ®Google Scholar
• Keck JW, Wenger JD, Bruden DL, Rudolph KM, Hurlburt DA, Hennessy TW, Bruce MG. PCV7-induced changes in pneumococcal carriage and invasive disease burden in Alaskan children. Vaccine 2014; 32:6478-84; PMID:25269095; http://dx.doi.org/10.1016/j.vaccine.2014.09.037
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, Sunakawa K, Ubukata K. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138:61-8; PMID:19538821; http://dx.doi.org/10.1017/S0950268809990239
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014; 20 Suppl 5:45-51; PMID:24313448; http://dx.doi.org/10.1111/1469-0691.12461
   PubMed Web of Science ®Google Scholar
• Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 2013; 9:1382-4; PMID:23732892; http://dx.doi.org/10.4161/hv.24692
   PubMed Web of Science ®Google Scholar
• Aliberti S, Mantero M, Mirsaeidi M, Blasi F. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 2014; 20 Suppl 5:52-8; PMID:24410778; http://dx.doi.org/10.1111/1469-0691.12518
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012; 30:4435-44; PMID:22542818; http://dx.doi.org/10.1016/j.vaccine.2012.04.052
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606; PMID:17714673; http://dx.doi.org/10.1016/S1473-3099(07)70210-4
   PubMed Web of Science ®Google Scholar
• Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, Oishi K. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine 2014; 32:1181-6; PMID:24120483; http://dx.doi.org/10.1016/j.vaccine.2013.09.060
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011; 29:2287-95; PMID:21255685; http://dx.doi.org/10.1016/j.vaccine.2011.01.029
   PubMed Web of Science ®Google Scholar
• Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7:919-28; PMID:21860256; http://dx.doi.org/10.4161/hv.7.9.15996
   PubMed Web of Science ®Google Scholar
• Oishi K, Tamura K, Akeda Y. Global control of pneumococcal infections by pneumococcal vaccines. Trop Med Health 2014; 42:83-6; PMID:25425955; http://dx.doi.org/10.2149/tmh.2014-S11
   PubMedGoogle Scholar
• Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines 2013; 12:1379-94; PMID:24195479; http://dx.doi.org/10.1586/14760584.2013.852475
   PubMed Web of Science ®Google Scholar
• Ruiz-Aragon J, Marquez Pelaez S, Molina-Linde JM, Grande-Tejada AM. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine 2013; 31:5349-58; PMID:24055349; http://dx.doi.org/10.1016/j.vaccine.2013.09.008
   PubMed Web of Science ®Google Scholar
• Martikainen JA, Soini EJ, Laine J, Ahman H, Postila V, Klemets P. Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults >/=50 years with underlying chronic medical conditions. J Eval Clin Pract 2014; 20:333-41; PMID:24813690; http://dx.doi.org/10.1111/jep.12131
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013; 30:263-76; PMID:23420119; http://dx.doi.org/10.1007/s40266-013-0060-5
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009; 30:189-209; PMID:19296419; http://dx.doi.org/10.1055/s-0029-1202938
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22; PMID:20200385; http://dx.doi.org/10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012; 55:e35-44; PMID:22652582; http://dx.doi.org/10.1093/cid/cis513
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:499-505; PMID:19556517; http://dx.doi.org/10.1164/rccm.200903-0488OC
   PubMed Web of Science ®Google Scholar
• Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One 2012; 7:e46133; PMID:23029408; http://dx.doi.org/10.1371/journal.pone.0046133
   PubMed Web of Science ®Google Scholar
• Usuf E, Bottomley C, Adegbola RA, Hall A. Pneumococcal carriage in sub-Saharan Africa–a systematic review. PLoS One 2014; 9:e85001; PMID:24465464; http://dx.doi.org/10.1371/journal.pone.0085001
   PubMed Web of Science ®Google Scholar
• Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, Akisanya A, Litchfield T, Nsekpong DE, Oluwalana C, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011; 8:e1001107; PMID:22028630; http://dx.doi.org/10.1371/journal.pmed.1001107
   PubMed Web of Science ®Google Scholar
• von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, Madhi SA, Zell ER, Verani JR, O'Brien KL, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371:1889-99; PMID:25386897; http://dx.doi.org/10.1056/NEJMoa1401914
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
   PubMed Web of Science ®Google Scholar
• Elberse KE, van der Heide HG, Witteveen S, van de Pol I, Schot CS, van der Ende A, Berbers GA, Schouls LM. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine 2012; 30:7644-51; PMID:22521844; http://dx.doi.org/10.1016/j.vaccine.2012.04.021
   PubMed Web of Science ®Google Scholar
• Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009; 27:4891-904; PMID:19520205; http://dx.doi.org/10.1016/j.vaccine.2009.05.061
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID:23440780
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged >/= 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909-17; PMID:24532544; http://dx.doi.org/10.1093/cid/ciu002
   PubMed Web of Science ®Google Scholar
• Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012; 61:394-5; PMID:22647745
   PubMedGoogle Scholar
• Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83; PMID:18990781
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585-93; PMID:23688527; http://dx.doi.org/10.1016/j.vaccine.2013.05.010
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014; 32:2364-74; PMID:24606865; http://dx.doi.org/10.1016/j.vaccine.2014.02.002
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822-5; PMID:25233284
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-23; PMID:18444818; http://dx.doi.org/10.1086/529142
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535-43; PMID:25801458; http://dx.doi.org/10.1016/S1473-3099(15)70044-7
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Shane A, Zhanel GG, Tyrrell GJ, Gilmour MW. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can J Microbiol 2012; 58:1008-17; PMID:22827750; http://dx.doi.org/10.1139/w2012-073
   PubMed Web of Science ®Google Scholar
• Chang Q, Stevenson AE, Croucher NJ, Lee GM, Pelton SI, Lipsitch M, Finkelstein JA, Hanage WP. Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. BMC Infect Dis 2015; 15:68; PMID:25887323; http://dx.doi.org/10.1186/s12879-015-0797-z
   PubMed Web of Science ®Google Scholar
• Munson S, Raluy-Callado M, Lambrelli D, Wasiak R, Eriksson D, Gray S. Clinical burden of pneumonia, meningitis and septicemia in Norway 2 years after 7-valent pneumococcal conjugate vaccine introduction. Scand J Public Health 2015; PMID:25979727
   PubMed Web of Science ®Google Scholar
• Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J. Non-invasive pneumococcal pneumonia in Portugal–serotype distribution and antimicrobial resistance. PLoS One 2014; 9:e103092; PMID:25075961; http://dx.doi.org/10.1371/journal.pone.0103092
   PubMedGoogle Scholar
• Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328-38; PMID:18844484; http://dx.doi.org/10.1086/592691
   PubMed Web of Science ®Google Scholar
• Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med 2015; 7:281ps8; PMID:25834107; http://dx.doi.org/10.1126/scitranslmed.aaa0722
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB, Lambert ND, Kirkland JL. A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol 2014; 29:62-8; PMID:24820347; http://dx.doi.org/10.1016/j.coi.2014.04.005
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14:428-36; PMID:23598398; http://dx.doi.org/10.1038/ni.2588
   PubMed Web of Science ®Google Scholar
• Aspinall R, Mitchell W. Reversal of age-associated thymic atrophy: treatments, delivery, and side effects. Exp Gerontol 2008; 43:700-5; PMID:18562142; http://dx.doi.org/10.1016/j.exger.2008.04.014
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5:133-9; PMID:14749784; http://dx.doi.org/10.1038/ni1033
   PubMed Web of Science ®Google Scholar
• Kang I, Hong MS, Nolasco H, Park SH, Dan JM, Choi JY, Craft J. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol 2004; 173:673-81; PMID:15210831; http://dx.doi.org/10.4049/jimmunol.173.1.673
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol 2005; 17:468-75; PMID:16098723; http://dx.doi.org/10.1016/j.coi.2005.07.020
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells – a reflection of T cell differentiation, cell senescence and host environment. Semin Immunol 2012; 24:365-72; PMID:22560928; http://dx.doi.org/10.1016/j.smim.2012.04.003
   PubMed Web of Science ®Google Scholar
• Miller JP, Allman D. The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol 2003; 171:2326-30; PMID:12928378; http://dx.doi.org/10.4049/jimmunol.171.5.2326
   PubMed Web of Science ®Google Scholar
• Labrie JE 3rd, Sah AP, Allman DM, Cancro MP, Gerstein RM. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med 2004; 200:411-23; PMID:15314072; http://dx.doi.org/10.1084/jem.20040845
   PubMed Web of Science ®Google Scholar
• Frasca D, Riley RL, Blomberg BB. Effect of age on the immunoglobulin class switch. Crit Rev Immunol 2004; 24:297-320; PMID:15663361; http://dx.doi.org/10.1615/CritRevImmunol.v24.i5.10
   PubMed Web of Science ®Google Scholar
• Cancro MP, Hao Y, Scholz JL, Riley RL, Frasca D, Dunn-Walters DK, Blomberg BB. B cells and aging: molecules and mechanisms. Trends Immunol 2009; 30:313-8; PMID:19540810; http://dx.doi.org/10.1016/j.it.2009.04.005
   PubMed Web of Science ®Google Scholar
• Stephan RP, Lill-Elghanian DA, Witte PL. Development of B cells in aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other growth factors. J Immunol 1997; 158:1598-609; PMID:9029095
   PubMed Web of Science ®Google Scholar
• Tsuboi I, Morimoto K, Hirabayashi Y, Li GX, Aizawa S, Mori KJ, Kanno J, Inoue T. Senescent B lymphopoiesis is balanced in suppressive homeostasis: decrease in interleukin-7 and transforming growth factor-beta levels in stromal cells of senescence-accelerated mice. Exp Biol Med (Maywood) 2004; 229:494-502; PMID:15169968
   PubMed Web of Science ®Google Scholar
• Keim C, Kazadi D, Rothschild G, Basu U. Regulation of AID, the B-cell genome mutator. Genes Dev 2013; 27:1-17; PMID:23307864; http://dx.doi.org/10.1101/gad.200014.112
   PubMed Web of Science ®Google Scholar
• Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. Exp Gerontol 2008; 43:718-28; PMID:18586079; http://dx.doi.org/10.1016/j.exger.2008.05.016
   PubMed Web of Science ®Google Scholar
• van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc 2007; 55:1438-44; PMID:17767688; http://dx.doi.org/10.1111/j.1532-5415.2007.01300.x
   PubMed Web of Science ®Google Scholar
• Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002; 169:4697-701; PMID:12391175; http://dx.doi.org/10.4049/jimmunol.169.9.4697
   PubMed Web of Science ®Google Scholar
• Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Capri M, Salvioli S, Valensin S, De Benedictis G, Di Iorio A, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 2005; 126:351-61; PMID:15621218; http://dx.doi.org/10.1016/j.mad.2004.08.028
   PubMed Web of Science ®Google Scholar
• Butcher SK, Chahal H, Nayak L, Sinclair A, Henriquez NV, Sapey E, O'Mahony D, Lord JM. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J Leukoc Biol 2001; 70:881-6; PMID:11739550
   PubMed Web of Science ®Google Scholar
• Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. J Leukoc Biol 2004; 76:291-9; PMID:15039467; http://dx.doi.org/10.1189/jlb.1103592
   PubMed Web of Science ®Google Scholar
• Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000; 18:1613-20; PMID:10689137; http://dx.doi.org/10.1016/S0264-410X(99)00495-8
   PubMed Web of Science ®Google Scholar
• Chelvarajan RL, Collins SM, Van Willigen JM, Bondada S. The unresponsiveness of aged mice to polysaccharide antigens is a result of a defect in macrophage function. J Leukoc Biol 2005; 77:503-12; PMID:15629885; http://dx.doi.org/10.1189/jlb.0804449
   PubMed Web of Science ®Google Scholar
• Simell B, Vuorela A, Ekstrom N, Palmu A, Reunanen A, Meri S, Kayhty H, Vakevainen M. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 2011; 29:1929-34; PMID:21236231; http://dx.doi.org/10.1016/j.vaccine.2010.12.121
   PubMed Web of Science ®Google Scholar
• Iyer AS, Ohtola JA, Westerink MA. Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic. Expert Rev Vaccines 2015; 14:85-97; PMID:25269650; http://dx.doi.org/10.1586/14760584.2015.963058
   PubMed Web of Science ®Google Scholar
• Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, Furumoto A, Tanimura S, Kityo C, Nagatake T, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962-8; PMID:18639599; http://dx.doi.org/10.1016/j.vaccine.2008.06.093
   PubMed Web of Science ®Google Scholar
• Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, Asami T, Yagi K, Kimizuka Y, Ishii M, et al. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study. Vaccine 2015; 33:327-32; PMID:25448102; http://dx.doi.org/10.1016/j.vaccine.2014.11.023
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 2009; 49:241-8; PMID:19522655; http://dx.doi.org/10.1086/599824
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594-602; PMID:23688525; http://dx.doi.org/10.1016/j.vaccine.2013.04.084
   PubMed Web of Science ®Google Scholar
• Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 2012; 7:453-61; PMID:23152675
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17:2493-500; PMID:10418894; http://dx.doi.org/10.1016/S0264-410X(99)00069-9
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/NEJMoa022678
   PubMed Web of Science ®Google Scholar
• Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010; 51:15-22; PMID:20504233; http://dx.doi.org/10.1086/653114
   PubMed Web of Science ®Google Scholar
• Ordonez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis 2014; 14:172; PMID:24679135; http://dx.doi.org/10.1186/1471-2334-14-172
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gauthier A, Keeping S, Carroll S. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014; 14:913-27; PMID:25189087; http://dx.doi.org/10.1586/14737167.2014.950232
   PubMed Web of Science ®Google Scholar
• Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine 2013; 31:6011-21; PMID:24148572; http://dx.doi.org/10.1016/j.vaccine.2013.10.024
   PubMed Web of Science ®Google Scholar
• Black S. The role of health economic analyses in vaccine decision making. Vaccine 2013; 31:6046-9; PMID:23968768; http://dx.doi.org/10.1016/j.vaccine.2013.08.008
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004; PMID:20211953; http://dx.doi.org/10.1136/bmj.c1004
   PubMed Web of Science ®Google Scholar
• Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010; 28:7063-9; PMID:20723631; http://dx.doi.org/10.1016/j.vaccine.2010.08.010
   PubMed Web of Science ®Google Scholar
• Kularatna S, Wijesinghe PR, Abeysinghe MR, Karunaratne K, Ekanayake L. Burden of invasive pneumococcal disease (IPD) in Sri-Lanka: deriving a reasonable measure for vaccine introduction decision making. Vaccine 2015; 33:3122-8; PMID:25976543; http://dx.doi.org/10.1016/j.vaccine.2015.04.093
   PubMed Web of Science ®Google Scholar
• Blau J, Hoestlandt C, D Clark A, Baxter L, Felix Garcia AG, Mounaud B, Mosina L. Strengthening national decision-making on immunization by building capacity for economic evaluation: implementing ProVac in Europe. Vaccine 2015; 33 Suppl 1:A34-9; PMID:25919171; http://dx.doi.org/10.1016/j.vaccine.2014.12.073
   PubMedGoogle Scholar